Event: 2026Q2 earnings call — Thursday, July 30, 2026
Baxter’s second-quarter report is primarily a credibility and execution checkpoint, not a near-term growth story. Management has already indicated that 2Q adjusted earnings should be broadly similar to 1Q’s $0.36 per share, while maintaining its full-year outlook for roughly flat organic revenue growth and $1.85–$2.05 of adjusted EPS.
The key investor question is therefore not simply whether BAX meets a likely-low quarterly bar. It is whether the company provides enough evidence that:
The shares closed at $24.70 on July 29, up about 29% year to date from $19.11 at year-end 2025. At the $1.95 midpoint of 2026 EPS guidance, that is roughly 12.7x adjusted EPS—suggesting the market has begun to underwrite the turnaround, but still needs proof of delivery.
At 1Q results, Baxter reiterated:
| FY26 outlook | Management guidance |
|---|---|
| Reported sales growth | Flat to +1% |
| Organic sales growth | Approximately flat |
| Adjusted EPS | $1.85–$2.05 |
For 2Q specifically, management subsequently characterized adjusted earnings as similar to 1Q. That points to approximately $0.36 adjusted EPS, absent a change in outlook at the report.
That setup makes the back half the real earnings event. If BAX earns $0.36 in both 1Q and 2Q, it would need roughly $1.23 of adjusted EPS in the second half—or about $0.62 per quarter—to reach the $1.95 full-year midpoint.
Management has explicitly framed this inflection as achievable: at the midpoint of guidance, it suggested adjusted operating margin should expand by more than 500 basis points from the first half to the second half, driven by improved volume leverage, the roll-off of elevated manufacturing costs, and benefits from cost actions.
Baxter’s 1Q26 results were mixed:
The earnings pressure was tied to tariffs, higher manufacturing costs, unfavorable factory absorption, and difficult comparisons. Importantly, management did not characterize these issues as merely transitory in every business; its message was that 2026 is a reset-and-stabilize year, with cleaner underlying earnings power expected after the first-half headwinds cycle.
This is the central issue.
Management indicated that 2Q should bear a larger portion of the manufacturing-variance burden—roughly more than $50 million incremental to 1Q’s approximately $20 million—yet still produce earnings similar to 1Q. Investors will want confirmation that these costs are now substantially captured and that the implied second-half margin recovery is still intact.
What would be constructive - Reaffirmed adjusted EPS guidance, ideally with more confidence around the midpoint. - Specific confirmation that excess manufacturing-cost inventory, tariff effects, and under-absorption are mostly first-half issues. - Evidence that restructuring and Baxter Growth and Performance System initiatives are translating to measurable cost and productivity benefits.
What would concern investors - A guidance range maintained only through a heavier back-end weighting. - New manufacturing, supply-chain, tariff, or pricing headwinds. - A weaker-than-expected gross-margin trajectory or vague commentary around 2H execution.
The 1Q organic decline was broad enough to matter:
| 1Q26 business trend | Organic growth |
|---|---|
| Infusion Therapies & Technologies | -5% |
| Advanced Surgery | +10% |
| Healthcare Systems & Technologies | -2% |
| Injectables & Anesthesia | -13% |
| Drug Compounding | +20% |
| Total Baxter | -1% |
Baxter does not need to produce high growth to support its 2026 thesis. It does need to show that the company is moving from declining organic revenue toward stability, consistent with its full-year outlook.
The most useful signal would be a sequential improvement in the company-wide organic-growth trend, supported by better performance in Infusion Therapies and Injectables & Anesthesia rather than solely continued strength in Drug Compounding and Advanced Surgery.
Baxter’s IV-fluid business is a major determinant of the recovery path. Management has concluded that hospital IV-conservation behavior is a structural “new normal,” rather than something that will fully reverse. The strategic response has been to resize the business for lower utilization and seek a return to low-single-digit growth over time.
For 2Q, the questions are:
A clean message that the IV business has stabilized—even if growth remains muted—would be important. Another downward reset to utilization or customer ordering patterns would pressure both the revenue and margin outlook.
The Novum IQ shipment and installation hold in the U.S. and Canada remains a meaningful overhang. Baxter expects no meaningful Novum sales while the hold is in place, with Spectrum IQ available as an alternative.
Investors should watch for: - any update on the timing and requirements for restarting broader Novum distribution and installation; - further remediation costs, return/exchange activity, or reserve adjustments; - signs of customer disruption or share loss in infusion pumps.
Injectables & Anesthesia fell 13% organically in 1Q, driven by supply constraints, weaker premix demand, and softer global anesthesia demand. The business is now part of Baxter’s newly structured Infusion Therapies & Platforms division.
There are reasons for cautious optimism: Baxter cited early operational improvement at a challenged manufacturing site and said its Ahmedabad facility is again available as an option for new product activity. But execution—not regulatory status alone—will determine whether supply availability, product launches, and mix can improve.
At March 31, Baxter had approximately:
Management is targeting leverage of approximately 3x by year-end 2026. This remains strategically important because it is the prerequisite to greater flexibility for internal investment, M&A, buybacks, or eventually a more meaningful shareholder-return policy.
The company cut its quarterly dividend to $0.01 per share, underscoring that deleveraging comes first. Management also expects $130 million–$140 million of 2026 TSA income related to Vantive, with a cited approximately $0.14 EPS headwind in 2027 as that income rolls off. The investor debate is whether cost actions and operational improvement can more than offset that headwind.
Starting in 2Q26, Baxter will report only two segments:
The former Pharmaceuticals segment is now included within Infusion Therapies & Platforms.
Healthcare Systems & Technologies (HST)
This is more than a cosmetic change. Investors should be careful comparing new segment margins and sales trends against the prior three-segment structure. Baxter furnished recast historical information on July 14, but the 2Q release will be the first earnings report under the new framework.
| Topic | What investors want to hear | Potential negative surprise |
|---|---|---|
| FY26 EPS outlook | Reaffirmed, with confidence in midpoint | Guidance cut or more pronounced 2H weighting |
| 2H margins | Manufacturing headwinds largely behind BAX | Further cost, tariff, or absorption pressure |
| Organic revenue | Sequential stabilization toward flat | Another broad organic decline |
| IV/Infusion | New utilization baseline is holding | Renewed inventory or volume deterioration |
| Novum IQ | Clearer remediation/restart path | Extended hold, elevated reserves, customer disruption |
| Injectables | Supply recovery and improved launch cadence | Ongoing shortages and price/mix erosion |
| Cash flow/deleveraging | Progress toward ~3x leverage | Weaker free cash flow or leverage slippage |
| 2027 setup | Cost actions can offset TSA roll-off | Limited visibility on post-TSA earnings power |
Bull case: Baxter executes the planned first-half-to-second-half transition. Organic sales stabilize, manufacturing headwinds ease, Advanced Surgery and Drug Compounding remain durable growth contributors, and cost actions begin to lift margins. In that scenario, the current valuation can look reasonable for a deleveraging turnaround with improved 2027 optionality.
Bear case: The company meets a soft 2Q EPS bar but fails to substantiate the magnitude of the second-half earnings recovery. A prolonged Novum hold, weak infusion utilization, continued injectables supply issues, or additional factory costs would make the full-year guide—and especially the 2027 bridge—less credible.
Most important takeaway: A modest 2Q beat alone should not be enough. The report needs to validate the operational bridge to the back half: stable organic demand, contained manufacturing costs, credible margin expansion, and steady deleveraging.